These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 18829119)
1. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. Marusic S; Thakker P; Pelker JW; Stedman NL; Lee KL; McKew JC; Han L; Xu X; Wolf SF; Borey AJ; Cui J; Shen MW; Donahue F; Hassan-Zahraee M; Leach MW; Shimizu T; Clark JD J Neuroimmunol; 2008 Nov; 204(1-2):29-37. PubMed ID: 18829119 [TBL] [Abstract][Full Text] [Related]
2. Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs. Thakker P; Marusic S; Stedman NL; Lee KL; McKew JC; Wood A; Goldman SJ; Leach MW; Collins M; Kuchroo VK; Wolf SF; Clark JD; Hassan-Zahraee M J Immunol; 2011 Aug; 187(4):1986-97. PubMed ID: 21746963 [TBL] [Abstract][Full Text] [Related]
3. The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation. Kong W; Hooper KM; Ganea D Brain Behav Immun; 2016 Mar; 53():59-71. PubMed ID: 26541818 [TBL] [Abstract][Full Text] [Related]
13. A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation. Guo W; Wang C; Wang X; Luo C; Yu D; Wang Y; Chen Y; Lei W; Gao X; Yao W Oncotarget; 2015 Oct; 6(30):28539-55. PubMed ID: 26384304 [TBL] [Abstract][Full Text] [Related]
14. Increasing acetyl-CoA metabolism attenuates injury and alters spinal cord lipid content in mice subjected to experimental autoimmune encephalomyelitis. Chevalier AC; Rosenberger TA J Neurochem; 2017 Jun; 141(5):721-737. PubMed ID: 28369944 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E and its mimetic peptide suppress Th1 and Th17 responses in experimental autoimmune encephalomyelitis. Wei J; Zheng M; Liang P; Wei Y; Yin X; Tang Y; Xue Y Neurobiol Dis; 2013 Aug; 56():59-65. PubMed ID: 23619428 [TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Min K; Yoon WK; Kim SK; Kim BH Arch Pharm Res; 2007 Oct; 30(10):1265-72. PubMed ID: 18038905 [TBL] [Abstract][Full Text] [Related]
17. Diminished cytokine and chemokine expression in the central nervous system of GMF-deficient mice with experimental autoimmune encephalomyelitis. Zaheer A; Sahu SK; Wu Y; Zaheer A; Haas J; Lee K; Yang B Brain Res; 2007 May; 1144():239-47. PubMed ID: 17316572 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of NADPH oxidase activation reduces EAE-induced white matter damage in mice. Choi BY; Kim JH; Kho AR; Kim IY; Lee SH; Lee BE; Choi E; Sohn M; Stevenson M; Chung TN; Kauppinen TM; Suh SW J Neuroinflammation; 2015 May; 12():104. PubMed ID: 26017142 [TBL] [Abstract][Full Text] [Related]
19. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Murphy AC; Lalor SJ; Lynch MA; Mills KH Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983 [TBL] [Abstract][Full Text] [Related]
20. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Ge Z; Da Y; Xue Z; Zhang K; Zhuang H; Peng M; Li Y; Li W; Simard A; Hao J; Yao Z; Zhang R Exp Neurol; 2013 Mar; 241():56-66. PubMed ID: 23261766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]